A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms DG-06
- Sponsors AstraZeneca
- 13 Aug 2024 Results published ina Daiichi Sankyo and AstraZeneca media release.
- 13 Aug 2024 According to a Daiichi Sankyo and AstraZeneca media release, ENHERTU has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more prior treatment regimens. Full approval for this indication will depend on whether a randomized controlled confirmatory clinical trial can demonstrate clinical benefit in this population.
- 06 May 2024 Status changed from active, no longer recruiting to completed.